Cilostazol is an antiplatelet agent and vasodilator used for the symptomatic relief of intermittent claudication. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co..
- Mechanism
- Curator reviewed
Cilostazol and several of its metabolites are cyclic AMP (cAMP) phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.
- Primary indication
- Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).Curator reviewed · 1 structured indication
- Formula / weight
- C20H27N5O2 · 369.4607 g/mol (avg)
- First approval
- United States, 1999
- Also known as
- Cilostazole
- Code names
- OPC-13013 · OPC-21
Resolves to
Clinical / RWD
Structure
InChIKey
RRGUKTPIGVIEKM-UHFFFAOYSA-NSMILESO=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2Targets
What you can answer from here — as of September 23, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Cilostazol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account